A major transformation in dementia diagnosis and care appears imminent and will depend on three major types of biomarkers: molecular imaging, blood-based biomarkers and cerebrospinal fluid biomarkers. Each modality has unique strengths and limitations that suggest its optimal uses in research, clinical trials and clinical diagnosis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests
Nature Medicine Open Access 21 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mintun, M. A. et al. N. Engl. J. Med. 384, 1691–1704 (2021).
van Dyck, C. H. et al. N. Engl. J. Med. 388, 9–21 (2022).
Angioni, D. et al. J. Prev. Alzheimers Dis. 9, 569–579 (2022).
Teunissen, C. E. et al. Lancet Neurol. 21, 66–77 (2021).
Janelidze, S. et al. Brain https://doi.org/10.1093/brain/awac333 (2022).
Janelidze, S. et al. JAMA Neurol. 78, 1375–1382 (2021).
Karikari, T. K. J. Alzheimers Dis. 90, 967–974 (2022).
Hansson, O. et al. Alzheimers Dement. 18, 2669–2686 (2022).
Schindler, S. E. Continuum 28, 822–833 (2022).
Bellomo, G. et al. Neurology 99, 195–205 (2022).
Bridel, C. et al. JAMA Neurol. 76, 1035–1048 (2019).
Shaw, L. M. et al. Alzheimers Dement. 14, 1505–1521 (2018).
Barthélemy, N. R. et al. Nat. Med. 26, 398–407 (2020).
Horie, K., Barthélemy, N. R., Sato, C. & Bateman, R. J. Brain 144, 515–527 (2021).
Horie, K. et al. Nat. Med. 28, 2547–2554 (2022).
Acknowledgements
S.E.S. receives research funding from NIA/NIH R01AG070941 and the Barnes-Jewish Hospital Foundation. A.A. receives institutional research grant or contract funding from NIA/NIH 1P30AG072980, AZ DHS CTR040636, the Foundation for NIH, Washington University St Louis and Gates Ventures.
Author information
Authors and Affiliations
Contributions
S.E.S. drafted the initial manuscript and A.A. provided extensive revisions.
Corresponding author
Ethics declarations
Competing interests
S.E.S. has received honoraria for educational presentations and serving as a member of the Biospecimen Review Committee with the National Centralized Repository for Alzheimer Disease and the Alzheimer Disease Center Clinical Task Force; has a non-compensated relationship as a board member with the Greater Missouri Alzheimer’s Association; has analyzed blood-based biomarker data provided by C2N Diagnostics to Washington University; and has served on a Scientific Advisory Board for Eisai. A.A. has received honoraria or support for consulting; participating in independent data safety monitoring boards; providing educational lectures, programs and materials; or serving on advisory boards for Biogen, Eisai, Lundbeck, Roche/Genentech and Novo Nordisk; and receives book royalties from Oxford University Press for a medical book on dementia; A.A’s institution receives or has received funding for clinical trial grants, contracts and projects from government, consortia, foundations and companies for which he serves or has served as contracted site PI.
Peer review
Peer review information
Nature aging thanks Ronald Petersen, Niklas Mattsson-Carlgren and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Rights and permissions
About this article
Cite this article
Schindler, S.E., Atri, A. The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer’s disease diagnostic revolution. Nat Aging 3, 460–462 (2023). https://doi.org/10.1038/s43587-023-00400-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-023-00400-6
